SEC Company Response from Q32 Bio Inc. (QTTB) (CIK 0001661998) (QTTB) — Mar 23, 2018
Q32 Bio Inc. (QTTB) (CIK 0001661998)
Date: March 23, 2018 · CIK: 0001661998 · Accession: 0001193125-18-094009
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-223409
Letter
Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Attention: Mr. Jeffrey Gabor Re: Homology Medicines, Inc. Registration Statement on Form S-1 Filed March 2, 2018 Registration No. 333-223409
Dear Mr. Gabor:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on March 27, 2018, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Homology Medicines, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Wesley Holmes of Latham & Watkins LLP, counsel to the Company, at (212) 906-1366, or in his absence, Peter Handrinos at (617) 948-6060, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Sincerely yours,
Homology Medicines, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP March 23, 2018 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attention: Mr. Jeffrey Gabor Re: Homology Medicines, Inc. Registration Statement on Form S-1 Filed March 2, 2018 Registration No. 333-223409 Dear Mr. Gabor: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on March 27, 2018, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Homology Medicines, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Wesley Holmes of Latham & Watkins LLP, counsel to the Company, at (212) 906-1366, or in his absence, Peter Handrinos at (617) 948-6060, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter. Sincerely yours, Homology Medicines, Inc. By: /s/ Arthur O. Tzianabos, Ph.D. Arthur O. Tzianabos, Ph.D. President and Chief Executive Officer cc: Peter N. Handrinos, Esq. Wesley C. Holmes, Esq.